Your session is about to expire
← Back to Search
PF-06755347 intravenous healthy participant for Thrombocytopenic Purpura
Study Summary
This trial will test a new drug for safety in healthy adults and adults with ITP. The drug's effects on the body will also be studied.
- Idiopathic Thrombocytopenic Purpura (ITP)
- Healthy Subjects
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Is it possible to register as a participant in this investigation?
"Eligible candidates for this medical trial will have to be under 55 years old, and must present with polyradiculoneuropathy or chronic inflammatory demyelinating. 67 individuals are being recruited."
Is enrollment into this experiment accessible to individuals currently?
"The information available on clinicaltrials.gov indicates that enrollment for this study is currently open to all eligible participants. The trial was first listed on July 17th 2017 and the most recent changes were applied November 22nd 2022."
Is the age limit to participate in this trial above thirty years?
"According to the parameters set forth by this study, enrollees must be aged 18 - 55. If one does not meet these requirements there are 82 trials available for individuals under 18 years old and 498 studies suitable for those over 65."
What deleterious effects can be anticipated from intravenous administration of PF-06755347?
"Due to the experimental nature of PF-06755347 intravenous, its safety rating has been assigned a score of 1. This reflects the current dearth of data available on efficacy and security levels."
Share this study with friends
Copy Link
Messenger